GlassScriptPhysician profile
Thad J Barkdull
NPI 1871524421
$6,851.61
in general payments reported to CMS, 2019-2025
57 companies · $822 in 2025
The $822 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $550 · 2021: $1,192 · 2022: $1,197 · 2023: $1,179 · 2024: $1,142 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,968 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.76 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,393.99 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astellas Pharma US INC | $544.47 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.43 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $359.64 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $320.07 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $319.47 | 2019-2022 | |
| Novo Nordisk INC | $273.03 | 2019-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $234.08 | 2019-2025 | |
| Lilly USA, LLC | $233.94 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Janssen Pharmaceuticals, INC | $209.39 | 2019-2024 | Xarelto |
| Abbott Laboratories | $205.82 | 2021-2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $201.14 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $180.04 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $155.90 | 2023-2025 | Voquezna |
| Glaxosmithkline, LLC. | $151.64 | 2020-2025 | Shingrix, Arexvy |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thad Barkdull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.